Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients [0.03%]
磷脂酰肌醇-3-激酶(PI3K)信号通路抑制剂治疗实体瘤：从实验室到临床
Filip Janku
Filip Janku
The phosphoinositide 3-kinase (PI3K) pathway is an intracellular signaling pathway that has regulatory roles in cell survival, proliferation, and differentiation, and a critical role in tumorigenesis. In cancer, multiple studies have invest...
Contralateral regional recurrence after elective unilateral neck irradiation in oropharyngeal carcinoma: A literature-based critical review [0.03%]
单侧选择性颈部放疗后口咽癌的对侧区域性复发：基于文献的批判性综述
Abrahim Al-Mamgani,Erik van Werkhoven,Arash Navran et al.
Abrahim Al-Mamgani et al.
Background: The head and neck region has rich regional lymphatic network, with a theoretical risk on contralateral metastasis from oropharyngeal cancer (OPC). There is a long-standing convention to irradiate the great maj...
Primož Strojan,Katherine A Hutcheson,Avraham Eisbruch et al.
Primož Strojan et al.
Radiotherapy (RT) is used to treat approximately 80% of patients with cancer of the head and neck. Despite enormous advances in RT planning and delivery, a significant number of patients will experience radiation-associated toxicities, espe...
Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review [0.03%]
抗PD-1药物治疗晚期黑色素瘤、肺癌、肾细胞癌及其他实体瘤患者的非典型反应：系统性回顾
Paola Queirolo,Francesco Spagnolo
Paola Queirolo
Anti-programmed death receptor 1 (PD-1) drugs nivolumab and pembrolizumab were recently approved for the treatment of advanced melanoma and other solid tumors. Atypical patterns of response (i.e. tumor shrinkage or stabilization after initi...
Matteo Lambertini,Oranite Goldrat,Angela Toss et al.
Matteo Lambertini et al.
Fertility and pregnancy-related issues represent one of the main areas of concerns for young women with breast cancer. Carrying a germline deleterious BRCA mutation adds additional burden on this regard due to the specific issues that shoul...
Treatment decisions in metastatic colorectal cancer - Beyond first and second line combination therapies [0.03%]
转移性结直肠癌的治疗决策：第一线和第二线联合疗法之外的选项
A Vogel,R D Hofheinz,S Kubicka et al.
A Vogel et al.
Median overall survival (OS) of patients with metastatic colorectal cancer (mCRC) has reached up to 30months in recent clinical trials of first line therapies. Following disease progression after the standard in both, 1st and 2nd line, comb...
Influence of non-measurable disease on progression-free survival in patients with metastatic breast cancer [0.03%]
不可测量疾病对转移性乳腺癌患者无进展生存期的影响
Hadar Goldvaser,Domen Ribnikar,Rouhi Fazelzad et al.
Hadar Goldvaser et al.
Background: The presence of non-measurable disease is common in metastatic breast cancer. It is unknown whether treatment effect on progression free survival (PFS) is consistent among patients with measurable and non-meas...
Fan Tang,Edwin Choy,Chongqi Tu et al.
Fan Tang et al.
Sarcomas are a rare group of malignant tumors originating from mesenchymal stem cells. Surgery, radiation and chemotherapy are currently the only standard treatments for sarcoma. However, their response rates to chemotherapy are quite low. ...
Long-term management of patients with hormone receptor-positive metastatic breast cancer: Concepts for sequential and combination endocrine-based therapies [0.03%]
激素受体阳性转移性乳腺癌的长期管理：序贯和联合内分泌治疗的概念
Adam M Brufsky
Adam M Brufsky
Treatment options for hormone receptor-positive (HR-positive) metastatic breast cancer (MBC) continue to increase in parallel with expanding knowledge about the complex biology of breast cancer subtypes and resistance mechanisms to endocrin...
Sagun Parakh,Hui K Gan,Adam C Parslow et al.
Sagun Parakh et al.
The development of HER2-directed monoclonal antibodies and tyrosine kinase inhibitors have provided benefits to cancer patients, as well as produced many insights into the biology of the ErbB receptor family. Current therapies based on ErbB...